Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,103

Document Document Title
WO/2018/111196A1
Disclosed is an isolated polypeptide comprising (C(w) – A(x) – B(y) – C(z) – D)n, wherein A comprises an immunoglobulin-like domain of VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), B comprises an immunoglobulin-like dom...  
WO/2018/110555A1
[Problem] To provide an anti-human CD73 antibody which is potentiated compared with the conventional antibodies and has an ability to recover a suppressed function of a human T cell which is suppressed in an AMP-dependent manner. [Soluti...  
WO/2018/112200A1
The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof, as well as FGF1-vagus targeting chimeric proteins which include an FGF1 portion (e.g., native FGF1or ...  
WO/2018/110374A1
The present invention addresses the problem of providing a strategy for therapy in a solid tumor area and a means useful for that purpose in order to further advance the clinical application of CAR therapy. A genetically modified lymphoc...  
WO/2018/107984A1
The present invention discloses a polypeptide containing a T helper cell epitope (Th epitope), which can serve as an immunostimulant of a B cell epitope or a peptide hapten of a target antigen. The invention also discloses a polypeptide ...  
WO/2018/111051A1
The present invention relates to a cytoplasmic transduction peptide and an intracellular messenger comprising the same. Compared with a virus-derived cytoplasmic transduction peptide, the intracellular messenger of the present invention ...  
WO/2018/110471A1
[Problem] To provide a fusion polypeptide that regulates the transcription of a target gene. [Solution] The present inventors provided a fusion polypeptide that includes a cell-membrane-permeable peptide, a DNA-binding polypeptide, and a...  
WO/2018/108106A1
Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized an...  
WO/2018/109771A1
Chimeric polypeptides comprising a first moiety comprising an NKp44-derived peptide fused to a second moiety comprising one or more cell penetrating peptides (CPP), and polynucleotides encoding the same. Further provided are methods for ...  
WO/2018/112069A1
This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in nee...  
WO/2018/111838A1
The technology described herein relates to controlled chemically- or light-induced rejoinder of split-recombinases. In some embodiments, compositions, methods, kits and systems are provided that relate to a split-recombinase system, wher...  
WO/2018/103631A1
The present invention provides a fusion protein of Slit2D2 (C386S) and HSA, and use thereof in the treatment and/or prevention of fibrotic diseases. In the fusion protein, cysteine at position 386 in Slit2D2 domain mutates into serine, w...  
WO/2018/107117A1
The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.  
WO/2018/103734A1
Disclosed are a chimeric antigen receptor (CAR) and the use thereof and a preparation method therefor, a T-cell containing the chimeric antigen receptor, a nucleic acid sequence encoding the chimeric antigen receptor, a vector comprising...  
WO/2018/102547A1
Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill TAG-72-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK)...  
WO/2018/100060A1
The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of syntenin. The peptide or peptide analog interacts with syntenin, blocking the native protein-protein interactions between syntenin ...  
WO/2018/100803A1
The purpose of the present invention is to provide a novel fluorescent protein. This FRET-type fluorescent protein complex is characterized by the following: including a first fluorescent protein and a second fluorescent protein; the fir...  
WO/2018/102678A1
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formu...  
WO/2018/101309A1
The present application relates to a WT1 helper peptide comprising an amino acid sequence of 9-30 residues including the amino acid sequence: KLSHL, and to the combination of said peptide and a cancer antigen peptide conjugate.  
WO/2018/097307A1
The present invention pertains to: a polypeptide that includes an antigen-binding domain and a conveying section having an inhibitory domain for inhibiting the antigen-binding activity of the antigen-binding domain, and that has a half-l...  
WO/2018/097308A1
The present invention pertains to: a ligand-binding molecule, the ligand binding activity of which is reduced by cleavage of a cleavage site thereof; a production method for the ligand-binding molecule; a complex formed of the ligand-bin...  
WO/2018/094542A1
The invention relates to an optogenetic expression system in yeast and a method for regulating the expression of a gene in a host cell, wherein the optogenetic expression system comprises at least two different photoreceptors, or light-s...  
WO/2018/096361A1
The present invention provides signal transduction modifying protein which comprises a domain which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (pITIM). The signal transduction modifying protein lacks a function...  
WO/2018/091544A1
The invention provides conjugates, comprising an organ or tissue targeting moiety linked to a biologically active moiety or linked to a diagnostic moiety. Such a biologically active or diagnostic moiety can be, for example, an oligonucle...  
WO/2018/093274A1
The invention relates to protein ligation technologies, purified or recombinant peptides, methods for making peptides and proteins with covalent bonds including reversible covalent bonds such as reversible intermolecular covalent bonds, ...  
WO/2018/094144A1
Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment...  
WO/2018/091739A1
The present invention provides multispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to GITR, and a second binding domain capable of specifically binding to CTLA-4. T...  
WO/2018/090144A1
A receptor is provided having a heterologous binding site that activates, when bound, a signaling domain related to the TNF receptor superfamily. Methods/uses of the foregoing in whole cell biosensors are also provided. There is also pro...  
WO/2018/087597A1
Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptid...  
WO/2018/088519A1
The present invention addresses the problem of providing a method for producing transgenic cells whereby a gene can be efficiently transferred into a number of arbitrary cells regardless of the kinds of cells, in particular, even into hu...  
WO/2018/087172A1
The present application relates to conjugates comprising interleukin 2 (IL2), and a mutant of tumour necrosis factor, such as tumour necrosis factor alpha (TNFα), and an antibody molecule. The antibody molecule preferably binds to an an...  
WO/2018/089335A1
The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an e...  
WO/2018/089664A1
The present disclosure provides (i) RNA-guided polypeptides (e.g., circular permuted Cas9 proteins) in which the N-terminal end of an N-terminal fragment of a parent RNA-guided polypeptide (e.g., a parent Cas9 protein) is fused (e.g., vi...  
WO/2018/089702A1
The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDN...  
WO/2018/089661A1
Presented herein, in certain embodiments, are compositions comprising synthetic polypeptides that specifically bind to MHC Class I.  
WO/2018/090045A1
An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, whi...  
WO/2018/088403A1
The present invention addresses the problem of providing a fragment antibody which can be easily produced as one having antigen-binding activity, and which has a greater ability to crystallize alone or as a complex with an antigen molecu...  
WO/2018/081897A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include S...  
WO/2018/084247A1
The present application pertains to a medicinal agent which is useful for preventing or treating avian influenza virus infection. More specifically, provided are: a multiple antigen peptide containing a dendritic core and peptides compri...  
WO/2018/081978A1
The present invention provides a method and system for improving a gene editing efficiency. Specifically, in the present invention, fusion protein formed after PEST short peptide and Cas9 protein are fused can remarkably improve the gene...  
WO/2018/085846A1
The invention relates to multi-functional antibiotic agents formed from antibiotics conjugated to microbial membrane disrupting peptides. These antibiotic-peptide conjugates are designed so that the conjugate simultaneously functions as ...  
WO/2018/085555A1
Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4...  
WO/2018/081898A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinat...  
WO/2018/085555A8
Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4...  
WO/2018/081806A3
Disclosed herein are compositions and methods for treating diseases characterized by expanded microsatellite repeats by impeding or inhibiting transcription of expanded microsatellite repeats.  
WO/2018/076342A1
A respiratory syncytial virus (RSV) vaccine comprising a recombinant fusion protein antigen. In one embodiment, the recombinant fusion protein antigen comprises a phosphoprotein (P) moiety, wherein the P moiety is a polypeptide that shar...  
WO/2018/076391A1
Provided are a PD-1 CAR NK-92 cell and a preparation method therefor and the use thereof. The PD-1 CAR NK-92 cell expresses a PD-1-CD8TM-4-1BB-CD3 ζ fusion protein in NK-92 cells. The PD-1 CAR NK-92 is obtained by infecting an NK92 cell...  
WO/2018/079702A1
The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of nativ...  
WO/2018/077189A1
Provided is a high-affinity soluble PD-1 molecule. In particular, provided is a programmed death receptor PD-1 molecule wherein the mutation occurs on the basis of the wild-type PD-1 molecule. In addition, the affinity between the PD-1 m...  
WO/2018/077098A1
Provided is a fusion protein used for treating an intestinal disease and having the following structure: R-L-P, where R is a GLP-2 receptor agonist, L is a connecting peptide chain, and P is a long-acting carrier protein. The fusion prot...  

Matches 1 - 50 out of 22,103